Meeting Coverage
AASLD
American Association for the Study of Liver Diseases
Latest REGENERATE analysis comes on heels of REVERSE flop
Latest AASLD Meetings
Plus: Normothermic machine perfusion for liver transplants and Noom Weight for NASH
With 10% efficacy at 6 months post-treatment, a finite HBV treatment may be on the horizon
Both 50- and 28-mg doses improved fibrosis vs placebo, without worsening of NASH
Ileal bile acid transporter inhibitor could become second drug for PFIC
Significant improvements in itching, bile acid levels for rare, life-threatening liver disorder
Phase II data suggest drug is well-tolerated and can reduce cravings in this group of patients
100% success rate even without the use of hepatitis B immunoglobulin
Patients who kept their blood pressure under 140/90 mm Hg had better kidney function at 1 year
More acute kidney injury reversals at 7 days and lower mortality with initiation at 12 hours
LCD also positively impacted patients' metabophenotype
A roundup of news from the AASLD annual meeting
UNOS data showed differences in waitlist removal, all-cause mortality based on obesity status
Women, racial/ethnic minorities most likely to experience discriminatory behavior
Post-transplant mortality still higher versus younger patients, but improving over time